Epizyme Announces DOT1L Inhibitor EPZ-5676 Shows Clinical, Biological Activity in Adult Patients with Acute Leukemias; Separately Reports PRMT5 Inhibitor Showed In Vitro, In Vivo Activity
Paul Quintaro